EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments

Anne Lynn S Chang, Lisa Zaba, Bernice Y Kwong

Journal of the American Academy of Dermatology · 2023

DOI: 10.1016/j.jaad.2022.07.062 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2023. Verfasst von Anne Lynn S Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: alschang@stanford.edu. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Keratinocytic cancers (KCs), specifically cutaneous squamous cell and basal cell carcinomas, can respond to topical, intralesional, or systemic immunotherapies, but cutaneous adverse events (CAEs) may occur. Understanding these risks, early recognition of these CAEs, and effective treatment may enable patients to continue their anticancer immunotherapies without dose impact. Immune checkpoint inhibitor-related CAEs after KCs can have multiple clinical presentations, with specific observed types including psoriasis and bullous pemphigoid. Cutaneous toxicities can require biopsies to confirm the diagnosis, especially in patients who are not responsive to topical or oral steroids, since the selection of biologic drugs depends on accurate diagnosis. Different types of CAEs from immune checkpoint inhibitors have been associated with different oncologic outcomes in various primary cancer types, and this remains to be determined for KC patients. CAE characterization and management after immune checkpoint inhibitors in KC patients is a rapidly growing field that needs specific and prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansImmune Checkpoint InhibitorsProspective StudiesImmunotherapyKeratinocytes

Stichwörter der Autor:innen

T-VECbasal cell carcinomabiologiccemiplimabcutaneous toxicityimiquimodimmune-related adverse eventsimmunotherapykeratinocyte carcinomaoncologic outcomespembrolizumabprogrammed cell death 1programmed deathrechallengesquamous cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: alschang@stanford.edu.
  • Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

Zitieren

APA

Chang, A. L. S., Zaba, L., & Kwong, B. Y. (2023). Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2022.07.062

Vancouver

Chang ALS, Zaba L, Kwong BY. Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments. Journal of the American Academy of Dermatology. 2023. doi:10.1016/j.jaad.2022.07.062

BibTeX
@article{Chang2023,
  author = {Chang, Anne Lynn S and Zaba, Lisa and Kwong, Bernice Y},
  title = {Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments},
  journal = {Journal of the American Academy of Dermatology},
  year = {2023},
  doi = {10.1016/j.jaad.2022.07.062}
}
Kostenlos starten →